CARM carismatx.com: Multiplikator Forward P/S
Carisma Therapeutics (CARM) adheres to environmental standards regarding biohazardous waste disposal. The forward P/S history on GURU.Markets captures these processes, where the 0.60 indicator expresses the state of the metric. This trend is driven by the uniqueness of the CAR-macrophage platform for combating tumors, although high production costs and uncertainty surrounding insurance reimbursements create significant financial risks for the issuer.
Rincian analitis perusahaan Carisma Therapeutics
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi saham perusahaan:
- statistik nilai buku emiten:
- data tingkat utang lan likuiditas finansial:
Total Utang marang Modal Carisma Therapeutics|CARM - Rasio tanggungan utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas carismatx.com|CARM - Gunggung kewajiban utang perusahaan|Rasio utang marang kapitalisasi buku Carisma Therapeutics Inc|CARM - Kewajiban jangka dawa perusahaan|Utang jangka cendhak perusahaan Carisma Therapeutics|Indikator likuiditas cepet carismatx.com
- rincian asil keuangan lan kelipatan valuasi:
CARM - Bathi pungkasan|Bathi mangsa ngarep Carisma Therapeutics|CARM - Rasio rega pasar marang bathi resik|Pangali Forward P/E Carisma Therapeutics|CARM - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA CARM|CARM - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Carisma Therapeutics|CARM - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan carismatx.com|CARM - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Carisma Therapeutics
- data total pendapatan lan volume dodolan:
Analisis komprehensif perusahaan:CARM (Carisma Therapeutics Inc.)
The development of Carisma Therapeutics (CARM) relies on internal development cycles and the commercialization of innovative drugs, which minimizes dependence on macroeconomic factors. An analysis of the company's expected P/S ratio allows for an assessment of the balance between market demand and projected revenue, determining the reliability of the price trend regardless of volume; high volatility in this indicator signals a speculative nature of the valuation and increased risks of a short-term price correction.
Pesaing Carisma Therapeutics (CARM)
Multiplikator Forward P/S ARGX (argenx.com)|BioNTech Group (BNTX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|ABIVAX - Multiplikator Forward P/S|ADMA - Multiplikator Forward P/S|Protagonist (PTGX) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan Immunovant Inc|Rasio rega marang prakiraan pendapatan Kiniksa Pharmaceuticals|Grifols Group (GRFS) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Adaptive Biotechnologies Corp (ADPT)|Rasio rega marang prakiraan pendapatan CLDX (Celldex Therapeutics)|Rasio rega marang prakiraan pendapatan Aurinia Pharma AUPH|Rega forward marang dodolan BCRX|VERA: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan DNTH (Dianthus Therapeutics)|Pharvaris N.V. (PHVS) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep AbCellera Biologics (ABCL)|TRML (Tourmaline Bio Inc) - Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan PGEN (Intrexon)|Multiplikator forward rega marang pendapatan PHAR (Pharming)|NKTR (Nektar) - Rega forward marang dodolan|Multiplikator Forward P/S UPB (upstreambio.com)|ZBIO (Zenas Biopharma Inc) - Rega mangsa ngarep marang pendapatan|IMNM - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Gossamer Bio Inc GOSS|KALV: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Septerna Pharma|PVLA (Pieris Corp) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan SVRA|Multiplikator Forward P/S RIGL|Multiplikator forward rega marang pendapatan AnaptysBio Corp ANAB|Astria Therapeutics Inc - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake enGene Holdings Inc. (ENGN)|RAPT Therapeutics Inc. - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Aerovate Therapeutics, Inc.|ACRS (Aclaris Therapeutics) - Multiplikator forward rega marang pendapatan|KYTX: Rasio rega marang pendapatan sing dikarepake|Rasio rega marang prakiraan pendapatan Tiziana Life Sciences|Cabaletta Bio, Inc (CABA) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan VTYX (Ventyx Biosciences)|Rasio kapitalisasi marang dodolan sing dikarepake theratech.com|Multiplikator Forward P/S AVTX (Avalo Therapeutics, Inc.)|Multiplikator Forward P/S Eledon Pharmaceuticals Inc. ELDN|AGEN: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan CLYM (Climb Bio, Inc)|ZURA: Multiplikator Forward P/S|aTyr Pharma, Inc. - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Adagene Inc.|IMA: Rega forward marang dodolan|Multiplikator Forward P/S STTK|Multiplikator forward rega marang pendapatan Equillium Bio EQ|Rasio rega marang prakiraan pendapatan Connect Biopharma CNTB|IMUX - Multiplikator forward rega marang pendapatan|ATRA - Rasio rega marang prakiraan pendapatan|InflaRx NV (IFRX) - Multiplikator forward rega marang pendapatan|XFOR (X4 Pharmaceuticals Inc.) - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Adicet Bio Inc. (ACET)|Rasio rega marang prakiraan pendapatan celularity.com|Multiplikator forward rega marang pendapatan inmunebio.com (INMB)|Rasio rega marang prakiraan pendapatan Barinthus Biotherapeutics PLC (BRNS)|Rasio kapitalisasi marang dodolan sing dikarepake Kezar Life Sciences Inc.|SAB Biotherapeutics, Inc - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Akari Therapeutics, Plc (AKTX)|ENLV: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan QTTB (q32bio.com)|GeoVax Labs Inc (GOVX) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan Edesa|Rasio rega marang prakiraan pendapatan iBio, Inc.|XTLB: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Bolt Biotherapeutics Inc. (BOLT)|HCW Biologics - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan aptevotherapeutics.com APVO|AIM - Multiplikator forward rega marang pendapatan|Aditxt - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake GRI Bio Corporation GRI|xortx.com (XRTX) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep reshapelifesciences.com (HIND)|Rasio rega marang prakiraan pendapatan Revelation Bio|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Indaptus Therapeutics, Inc. INDP|Rasio rega marang prakiraan pendapatan BiondVax Pharmaceuticals (SCNI)|Multiplikator forward rega marang pendapatan CalciMedica CALI|Rasio rega marang prakiraan pendapatan Affimed AFMD|ALLK - Multiplikator forward rega marang pendapatan|HOOKIPA Pharma, Inc. - Multiplikator Forward P/S|Rega forward marang dodolan IGMS (igmbio.com)|ITOS (iTeos Therapeutics, Inc.) - Multiplikator forward rega marang pendapatan|Ocean Biomedical Corp (OCEA) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan TC BioPharm (Holdings) PLC|Multiplikator Forward P/S thirdharmonicbio.com
